Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

Nature Medicine

Volumn 24, Issue 6, 2018, Pages 739-748

  Norelli, Margherita ^a,b   Camisa, Barbara ^a   Barbiera, Giulia ^c   Falcone, Laura ^a   Purevdorj, Ayurzana ^a   Genua, Marco ^c   Sanvito, Francesca ^a   Ponzoni, Maurilio ^a   Doglioni, Claudio ^a   Cristofori, Patrizia ^c   Traversari, Catia ^d   Bordignon, Claudio ^b,d   Ciceri, Fabio ^a,b   Ostuni, Renato ^c   Bonini, Chiara ^a,b   Casucci, Monica ^a   Bondanza, Attilio ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^d MOLMED S P A   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANAKINRA; CD14 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; TOCILIZUMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; NEUROTOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE SYNDROME; DISEASE FREE SURVIVAL; FEMALE; FEVER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LETHALITY; LEUKEMIA FREE SURVIVAL; MALE; MENINGITIS; MONOCYTE; MONONUCLEAR CELL; MOUSE; NEUROTOXICITY; NEWBORN; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REPEATED DRUG DOSE; ADOPTIVE IMMUNOTHERAPY; ANIMAL; HEMATOPOIETIC STEM CELL; IMMUNOLOGY; LEUKEMIA; METABOLISM; PATHOLOGY; SYNDROME; TUMOR CELL LINE;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; INTERLEUKIN-6; LEUKEMIA; MICE; MONOCYTES; NEUROTOXINS; RECEPTORS, CHIMERIC ANTIGEN; SYNDROME;

EID: 85047813147     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/s41591-018-0036-4     Document Type: Article

References (42)

1. Brentjens, R. J.,et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817-4828 (2011).
2. Savoldo, B.,et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121, 1822-1826 (2011).
3. Kochenderfer, J. N.,et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimericantigen-receptor-transduced T cells. Blood 119, 2709-2720 (2012).
4. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733 (2011).
5. Grupp, S. A.,et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518 (2013).
6. Neelapu, S. S.,et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N. Engl. J. Med. 377, 2531-2544 (2017).
7. Maude, S. L.,et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439-448 (2018).
8. Davila, M. L.,et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25 (2014).
9. Turtle, C. J.,et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126, 2123-2138 (2016).
10. Turtle, C. J.,et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J. Clin. Oncol. 35, 3010-3020 (2017).
11. Teachey, D. T.,et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 6, 664-679 (2016).
12. Lee, D. W.,et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188-195 (2014).
13. Park, J. H.,et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449-459 (2018).
14. Topp, M. S.,et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 16, 57-66 (2015).
15. Bondanza, A.,et al. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood 107, 1828-1836 (2006).
16. Mastaglio, S.,et al. NY-ESO-1 TCR single edited central memory and memory stem T cells to treat multiple myeloma without inducing GvHD. Blood 130, 606-618 (2017).
17. Casucci, M.,et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood 122, 3461-3472 (2013).
18. Gattinoni, L., Speiser, D. E., Lichterfeld, M. & Bonini, C. T memory stem cells in health and disease. Nat. Med. 23, 18-27 (2017).
19. Nijmeijer, B. A., Willemze, R. & Falkenburg, J. H. An animal model for human cellular immunotherapy: specific eradication of human acute lymphoblastic leukemia by cytotoxic T lymphocytes in NOD/scid mice. Blood 100, 654-660 (2002).
20. Rongvaux, A.,et al. Human hemato-lymphoid system mice: current use and future potential for medicine. Annu. Rev. Immunol. 31, 635-674 (2013).
21. Shultz, L. D.,et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J. Immunol. 154, 180-191 (1995).
22. Takenaka, K.,et al. Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat. Immunol. 8, 1313-1323 (2007).
23. Billerbeck, E.,et al. Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2R? (null) humanized mice. Blood 117, 3076-3086 (2011).
24. Wils, E. J.,et al. Stem cell factor consistently improves thymopoiesis after experimental transplantation of murine or human hematopoietic stem cells in immunodeficient mice. J. Immunol. 187, 2974-2981 (2011).
25. Koo, G. C., Hasan, A. & O'Reilly, R. J. Use of humanized severe combined immunodeficient mice for human vaccine development. Expert Rev. Vaccines 8, 113-120 (2009).
26. Strowig, T.,et al. Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J. Exp. Med. 206, 1423-1434 (2009).
27. Lan, P., Tonomura, N., Shimizu, A., Wang, S. & Yang, Y. G. Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation. Blood 108, 487-492 (2006).
28. Bouma, G.,et al. NOD mice have a severely impaired ability to recruit leukocytes into sites of inflammation. Eur. J. Immunol. 35, 225-235 (2005).
29. Patel, A. A.,et al. The fate and lifespan of human monocyte subsets in steady state and systemic inflammation. J. Exp. Med. 214, 1913-1923 (2017).
30. Bondanza, A.,et al. IL-7 receptor expression identifies suicide gene-modified allospecific CD8+ T cells capable of self-renewal and differentiation into antileukemia effectors. Blood 117, 6469-6478 (2011).
31. Kochenderfer, J. N.,et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33, 540-549 (2015).
32. Turtle, C. J.,et al. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptormodified T cells. Sci. Transl. Med. 8, 355ra116 (2016).
33. Schuster, S. J.,et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N. Engl. J. Med. 377, 2545-2554 (2017).
34. Hunter, C. A. & Jones, S. A. IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 16, 448-457 (2015).
35. Singh, N.,et al. Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function. Cytotherapy 19, 867-880 (2017).
36. Gust, J.,et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 7, 1404-1419 (2017).
37. Goldbach-Mansky, R.,et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1? inhibition. N. Engl. J. Med. 355, 581-592 (2006).
38. Fox, E.,et al. The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates. J. Neuroimmunol. 223, 138-140 (2010).
39. Kaneko, S.,et al. IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood 113, 1006-1015 (2009).
40. Zheng, G. X.,et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 8, 14049 (2017).
41. Levine, J. H.,et al. Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis. Cell 162, 184-197 (2015).
42. Villani, A. C.,et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science 356, eaah4573 (2017).